Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Subjects With Malignant Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04424641
Recruitment Status : Recruiting
First Posted : June 11, 2020
Last Update Posted : December 14, 2020
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Genmab

Brief Summary:
The purpose of the trial is to evaluate the safety, determine the recommended phase 2 dose, and assess preliminary clinical activity of GEN1044 in subjects with solid tumors.

Condition or disease Intervention/treatment Phase
Dose Escalation Part: Locally Advanced or Metastatic Solid Tumor(s) Expansion Part: Prostate Cancer Expansion Part: Esophageal Cancer Expansion Part: Triple Negative Breast Cancer (TNBC) Expansion Part: Squamous Cell Carcinoma of Head and Neck (SCCHN) Expansion Part: Non-small Cell Lung Cancer (NSCLC) Expansion Part: Bladder Cancer Expansion Part: Uterine Cancer Biological: GEN1044 is an IgG1 bispecific antibody targeting CD3 and 5T4. Phase 1 Phase 2

Detailed Description:
The trial is an open-label, multi-center safety trial of GEN1044. The trial consists of two parts: a dose escalation part (phase 1) and an expansion part (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined from phase 1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 378 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors
Actual Study Start Date : July 15, 2020
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : June 2024


Arm Intervention/treatment
Experimental: Treatment
Open Label, single arm where GEN1044 will be administered
Biological: GEN1044 is an IgG1 bispecific antibody targeting CD3 and 5T4.
GEN1044 will be administered (intravenously) in cycles of 21 days. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.




Primary Outcome Measures :
  1. Dose Escalation Part: Dose Limiting Toxicities (DLTs) [ Time Frame: DLTs will be assessed during the first cycle (21 days) in each cohort ]
    To assess recommended phase 2 dose

  2. Adverse Events (AEs) [ Time Frame: AEs are collected throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    To assess the safety and tolerability of GEN1044 throughout the treatment period of patients participating in the trial

  3. Expansion Part: Evaluate anti-tumor activity [ Time Frame: Response assessment will be evaluated through trial completion, up to 5 years after last patient first visit. ]
    Reduction in tumor size according to response assessment (Objective Response Rate)

  4. Safety Laboratory parameters (Hematology: Hematocrit, Hemoglobin Mean platelet volume, Platelet Count, Red Blood Cell Count, White Blood Cell Count) ) [ Time Frame: Safety Laboratory parameters are collected throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    To assess the safety and tolerability of GEN1044 throughout the treatment period of patients participating in the trial

  5. Safety Laboratory parameters (Biochemistry: ALP, ALT, Amylase, AST, Bilirubin, BUN, Calcium, Chloride, Creatinine, CRP, Albumin, GGT, Glucose, Glycosylated hemoglobin, LDH, Lipase, Magnesium, Nitrogen, Phosphate, Potassium, Protein, Sodium, Uric acid) [ Time Frame: Safety Laboratory parameters are collected throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    To assess the safety and tolerability of GEN1044 throughout the treatment period of patients participating in the trial

  6. Safety Laboratory parameters (Coagulation: Prothrombin time, International normalized ratio, Activated partial thromboplastin time) [ Time Frame: Safety Laboratory parameters are collected throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    To assess the safety and tolerability of GEN1044 throughout the treatment period of patients participating in the trial

  7. Safety Laboratory parameters (Urinalysis: Leukocytes, Protein) [ Time Frame: Safety Laboratory parameters are collected throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    To assess the safety and tolerability of GEN1044 throughout the treatment period of patients participating in the trial


Secondary Outcome Measures :
  1. To establish the pharmacokinetic profile (PK) profile of GEN1044 [ Time Frame: Assed throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Rate at which the drug is removed from the body (clearance)

  2. To establish the PK profile of GEN1044 [ Time Frame: Assed throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Amount of drug in the body (volume of distribution)

  3. To establish the PK profile of GEN1044 [ Time Frame: Assed throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Area-under-the-concentration-time curve (AUC0-C last)

  4. To establish the PK profile of GEN1044 [ Time Frame: Assed throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Maximum concentration of GEN1044 (Cmax) after dosing

  5. To establish the PK profile of GEN1044 [ Time Frame: Assed throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Time after dosing at which the maximum drug concentration was observed (Tmax)

  6. To establish the PK profile of GEN1044 [ Time Frame: PK parameter will be assed throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Time after dosing at which the lowest drug concentration is observed before the next dose is administered (CTrough)

  7. To establish the PK profile of GEN1044 [ Time Frame: PK parameter will be assed throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Elimination half-life of the drug (T1/2)

  8. Evaluate immunogenicity of GEN1044 [ Time Frame: ADA are collected throughout trial until the end of the safety follow-up period (30 days after last dose) ]
    Anti-drug antibody response (ADA)

  9. Expansion Part: Evaluate efficacy [ Time Frame: Assessment will be made through trial completion, up to 5 years after last patient first visit. ]
    Progression free survival (Overall survival)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

Dose Escalation Part:

• Subject with locally advanced or metastatic solid tumor(s) (excluding subjects with primary central nervous system [CNS] tumors), who has experienced disease progression while on standard therapy or is intolerant of, or not eligible for, standard therapy.

Expansion Part:

• Must have an advanced or metastatic, pathologically confirmed diagnosis of one of the following tumors: Uterine Cancer, Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Non-small Cell Lung Cancer (both adenocarcinoma (ACC) and squamous cell carcinoma (SCC) (NSCLC/ACC and NSCLC/SCC), Bladder Cancer.

Both Parts:

  • Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for the trial, and is willing to participate in the trial prior to any trial related assessments or procedures.
  • Must have measurable disease according to response assessment criteria relevant to the tumor type.
  • Must have an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-1 at Screening and on C1D1.
  • A woman of reproductive potential must agree to use adequate contraception during the trial and for 4 months after the last GEN1044 administration. Adequate contraception is defined as highly effective methods of contraception.

Key Exclusion Criteria (both parts):

  1. Has an uncontrolled intercurrent illness, including but not limited to:

    1. Ongoing or active infection requiring intravenous treatment with anti-infective therapy
    2. Symptomatic congestive heart failure (grade III or IV as classified by the New York Heart Association), unstable angina pectoris or cardiac arrhythmia.
    3. Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, despite optimal medical management.
    4. Ongoing or recent evidence of significant autoimmune disease Subjects with a history of grade 3 or higher irAEs that led to treatment discontinuation.
    5. Subjects with a prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
    6. History of chronic liver disease or evidence of hepatic cirrhosis.
    7. History of non-infectious pneumonitis that has required steroids, or currently has pneumonitis.
    8. History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of GEN1044.
    9. Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
  2. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new or symptomatic brain metastases or stroke.
  3. Prior therapy:

    Radiotherapy: Radiotherapy within 14 days prior to first GEN1044 administration. Palliative radiotherapy will be allowed.

  4. Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1044 administration. Toxicities from previous anti-cancer therapies that have not resolved.
  5. Has a history of ≥ grade 2 cytokine release syndrome (CRS) with other CD3-based bispecifics, or a history of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as known or has known allergies, hypersensitivity, or intolerance to GEN1044 or its excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04424641


Contacts
Layout table for location contacts
Contact: Genmab Trial Information +4570202728 clinicaltrials@genmab.com

Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine Not yet recruiting
Saint Louis, Missouri, United States, 63110
Contact: Ramaswamy Govindan, MD         
United States, Tennessee
Tennesse Oncology, PLLC - Nashville Recruiting
Nashville, Tennessee, United States, 37203
Contact: Melissa Johnson, MD         
United States, Texas
MD Anderson Cancer center Not yet recruiting
Houston, Texas, United States, 77054
Contact: Aung Naing, MD         
Denmark
Rigshospitalet (Copenhagen University Hospital) Recruiting
Copenhagen, Denmark, 2100
Contact: Kristian Rohrberg, MD         
Israel
Chaim Sheba Medical Center Recruiting
Ramat Gan, Israel, 5265601
Contact: Eytan Ben-Ami, MD         
Spain
Hospital Universitari Vall d'Hebron Recruiting
Barcelona, Spain, 8035
Contact: Elena Garralda Cabanas, MD         
Fundacion Jimenez Diaz Recruiting
Madrid, Spain, 28040
Contact: Victor Moreno, MD         
Sponsors and Collaborators
Genmab
AbbVie
Investigators
Layout table for investigator information
Study Director: Roberto Oliveri, MD Genmab
Layout table for additonal information
Responsible Party: Genmab
ClinicalTrials.gov Identifier: NCT04424641    
Other Study ID Numbers: GCT1044-01
First Posted: June 11, 2020    Key Record Dates
Last Update Posted: December 14, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Triple Negative Breast Neoplasms
Uterine Neoplasms
Squamous Cell Carcinoma of Head and Neck
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Head and Neck Neoplasms
Breast Neoplasms
Breast Diseases
Skin Diseases
Genital Neoplasms, Female
Uterine Diseases
Antibodies
Antibodies, Bispecific
Immunologic Factors
Physiological Effects of Drugs